Technical Analysis for COCP - Cocrystal Pharma, Inc.

Grade Last Price % Change Price Change
B 2.15 4.42% 0.09
COCP closed unchanged on Wednesday, November 20, 2024, on 60 percent of normal volume.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up

Date Alert Name Type % Chg
Calm After Storm Range Contraction 4.42%
Wide Bands Range Expansion 4.42%
Gapped Down Weakness 4.42%
Calm After Storm Range Contraction 4.42%
Wide Bands Range Expansion 4.42%
Upper Bollinger Band Touch Strength 4.42%
Down 3 Days in a Row Weakness 4.42%
Calm After Storm Range Contraction 3.92%
Wide Bands Range Expansion 3.92%
Upper Bollinger Band Touch Strength 3.92%

   Recent Intraday Alerts

Alert Time
Upper Bollinger Band Resistance about 4 hours ago
Gap Down Partially Closed about 4 hours ago
Gap Down Closed about 4 hours ago
Reversed from Down about 4 hours ago
2x Volume Pace about 4 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Cocrystal Pharma, Inc. Description

Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. CC-31244 is a Phase 2a ready broad-spectrum novel non-nucleoside replication inhibitor of HCV. Phase 1b studies in HCV infected patients showed the largest reduction in viral load of any non-nucleoside inhibitor tested to date. The next step for CC-31244 is clinical trials as part of a cocktail for ultra-short therapy of 2 to 4 weeks. The lead candidate for influenza has advanced to IND-enabling studies. It is effective in animal models against both the pandemic and seasonal strains of influenza. In addition, the Company has a pipeline of promising early preclinical programs. Two private investors own approximately 60% of the Company, including the Frost Group. OPKO Health, Inc., Brace Pharma Capital, LLC and Teva Pharmaceuticals Industries, Ltd. are corporate investors.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biology Coronavirus Influenza Viruses Microbiology Virus Antiviral Drug Biocides HCV Influenza Viruses Opko Health Pharmaceuticals Industries

Is COCP a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 3.1
52 Week Low 1.325
Average Volume 19,497
200-Day Moving Average 1.85
50-Day Moving Average 1.84
20-Day Moving Average 1.87
10-Day Moving Average 1.93
Average True Range 0.18
RSI (14) 58.68
ADX 31.02
+DI 32.67
-DI 14.14
Chandelier Exit (Long, 3 ATRs) 1.91
Chandelier Exit (Short, 3 ATRs) 2.19
Upper Bollinger Bands 2.17
Lower Bollinger Band 1.58
Percent B (%b) 0.81
BandWidth 31.69
MACD Line 0.06
MACD Signal Line 0.02
MACD Histogram 0.0319
Fundamentals Value
Market Cap 20.96 Million
Num Shares 10.2 Million
EPS -1.97
Price-to-Earnings (P/E) Ratio -1.05
Price-to-Sales 92.45
Price-to-Book 0.51
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.30
Resistance 3 (R3) 2.30 2.23 2.26
Resistance 2 (R2) 2.23 2.17 2.22 2.25
Resistance 1 (R1) 2.14 2.13 2.18 2.14 2.23
Pivot Point 2.07 2.07 2.09 2.06 2.07
Support 1 (S1) 1.98 2.01 2.03 1.98 1.89
Support 2 (S2) 1.91 1.97 1.91 1.87
Support 3 (S3) 1.82 1.91 1.86
Support 4 (S4) 1.82